Functional Properties of p-Anisoylated Plasmin-Staphylokinase Complex

Summary

The kinetic and fibrinolytic properties of a reversibly acylated stoichiometric complex between human plasmin and recombinant staphylokinase (plasmin-STAR complex) were evaluated. The acylation rate constant of plasmin-STAR by p-amidinophenyl-p’-anisate-HCI was 52 M^-1 s^-1 and its deacylation rate constant 1.2 × 10^-4 s^-1 (t½ of 95 min) which are respectively 50-fold and around 3-fold lower than for the plasmin-streptokinase complex. The acylated complex was stable as evidenced by binding to lysine-Sepharose. However, following an initial short lag phase, the acylated plasmin-STAR complex activated plasminogen at a similar rate as the unblocked complex, whereas the acylated plasmin-streptokinase complex did not activate plasminogen. These findings indicate that STAR, unlike streptokinase, dissociates from its acylated complex with plasmin in the presence of excess plasminogen. In agreement with this hypothesis, the time course of the lysis of a ¹²⁵I-fibrin labeled plasma clot submerged in citrated human plasma, is similar for acylated plasmin-STAR, unblocked plasmin-STAR and free STAR (50% clot lysis in 2 h requires 12 nM of each agent). The plasma clearances of STAR-related antigen following bolus injection in hamsters were 1.0 to 1.5 ml/min for acylated plasmin-STAR, unblocked plasmin-STAR and free STAR, as a result of short initial half-lives of 2.0 to 2.5 min.

The dissociation of the anisoylated plasmin-STAR complex and its consequent rapid clearance suggest that it has no apparent advantages as compared to free STAR for clinical thrombolysis.

• References

• 1 Lack CH. Staphylokinase: an activator of plasma protease. Nature 1948; 161: 559-560
• 2 Lewis JH, Ferguson JH. A proteolytic enzyme system of the blood III. Activation of dog serum profibrinolysin by staphylokinase. Am J Physiol 1951; 166: 594-603
• 3 Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-11832
• 4 Kowalska-Loth B, Zakrzewski K. The activation by staphylokinase of human plasminogen. Acta Biochim Pol 1975; 22: 327-339
• 5 Ericson R. The mechanism of the activation of plasminogen by staphylokinase. Chem Abstr 1977; 86: 202 (abstract 67386Z)
• 6 Sakai M, Watanuki M, Matsuo O. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of α₂-plasmin inhibitor. Biochem Biophys Res Commun 1989; 162: 830-837
• 7 Cederholm-Williams SA, De Cock F, Lijnen HR, Collen D. Kinetics of the reactions between streptokinase, plasmin and α₂-antiplasmin. Eur J Biochem 1979; 100: 125-132
• 8 Lewis JH, Kerber CW, Wilson JH. Effects of fibrinolytic agents and heparin on intravascular clot lysis. Am J Physiol 1964; 207: 1044-1048
• 9 Kanai K. Fibrinolysis by staphylokinase in vivo. Biol Abstr 1986; 81: 748 (abstract 65436)
• 10 Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemostas 1991; 66: 468-473
• 11 Collen D, De Cock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-242
• 12 Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties towards arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993; 87: 0996-1006
• 13 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. (in press)
• 14 Verstraete M. A far-raching program: rapid, safe, and predictable thrombolysis in man. In: Fibrinolysis Kline DL, Reddy KNN. (eds) CRC Press; 1980: 185-200
• 15 Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acylenzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505-508
• 16 AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990; 335: 427-431
• 17 GREAT Group. Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. Br Med J 1992; 305: 548-553
• 18 Collen D, Silence K, Demarsin E, De Mol M, Lijnen HR. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 203-213
• 19 Lijnen HR, Van Hoef B, Vandenbossche L, Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 214-225
• 20 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
• 21 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
• 22 Lijnen HR, Van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 1986; 884: 402-408
• 23 Wiman B. Primary structure of the B-chain of human plasmin. Eur J Biochem 1977; 76: 129-137
• 24 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem 1987; 262: 10855-10862
• 25 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
• 26 Busby SJ, Mulvihill E, Rao D, Kumar AA, Lioubin P, Heipel M, Sprecher C, Halfpap L, Prunkard D, Gambee J, Foster DC. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity. J Biol Chem 1991; 266: 15286-15292
• 27 Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser⁷⁴⁰ → Ala) and plasmin resistant scu-PA (Lys¹⁵⁸ → Glu). J Biol Chem 1990; 265: 5232-5236
• 28 Wiman B. Affinity-chromatographic purification of human α₂-antiplasmin. Biochem J 1980; 191: 229-232
• 29 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide l,3,4,6-tetrachloro-3a,6a-diphenyl-gly-coluril. Biochem Biophys Res Commun 1978; 80: 849-857
• 30 Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a ¹²⁵I-containing acylating agent. Biochem J 1973; 133: 529-539
• 31 Smith RAG, Garman AJ, Morgan GS. Structure-activity relationships for the formation and breakdown of acylated fibrinolytic enzymes. Progr Fibrinolysis 1985; VII: 227-231
• 32 Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 1962; 237: 3245-3249
• 33 Collen D, Lijnen HR, De Cock F, Durieux JP, Loffet A. Kinetic properties of tripeptide lysyl chloromethylketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. Biochim Biophys Acta 1980; 165: 158-166
• 34 Zamarron C, Lijnen HR, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 19-23
• 35 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 36 Gibaldi M, Perrier D. In: Pharmacokinetics Marcel Dekker. New York: ; 1983: 045-111
• 37 Smith RAG. Non-exchange of streptokinase from anisoylated plasminogen streptokinase activator complex and other acylated streptokinase plasminogen complexes. Drugs 1987; 33: 075-079
• 38 Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M, Lijnen HR, Behnke D. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem 1993; 268: 8284-8289
• 39 Ferres H, Hibbs M, Smith RAG. Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex. Drugs 1987; 33 (Suppl. 03) 80-82
• 40 Silence K, Collen D, Lijnen HR. Interaction between staphylokinase, plasmin(ogen) and α₂-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by α₂-antiplasmin. Biol Chem. (in press)
• 41 Staniforth DH, Smith RAG, Hibbs M. Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers. Eur J Clin Pharmacol 1983; 24: 751-756
• 42 Fears R, Ferres H, Greenwood H, Standring R, Valencia O. Comparison of fibrinolytic and immunodetection methods for the measurement of APSAC pharmacokinetics in patients with acute myocardial infarction. Fibrinolysis 1990; 4: 101-105